PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34282472-1	2021	PURPOSE: Pemigatinib (INCB054828), a potent and selective oral fibroblast growth factor receptor 1-3 inhibitor, is a Biopharmaceutical Classification System class II compound with good permeability and pH-dependent solubility that is predominantly metabolized by cytochrome P450 (CYP) 3A.	Pemigatinib	9-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	263-287	
34282472-1	2021	PURPOSE: Pemigatinib (INCB054828), a potent and selective oral fibroblast growth factor receptor 1-3 inhibitor, is a Biopharmaceutical Classification System class II compound with good permeability and pH-dependent solubility that is predominantly metabolized by cytochrome P450 (CYP) 3A.	Pemigatinib	22-32	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	263-287	
35506332-8	2022	The recommendation based on this simulation and clinical data is to reduce pemigatinib dose for coadministration with strong and moderate CYP3A4 inhibitors.	Pemigatinib	75-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	138-144	
34169560-2	2022	Pemigatinib is predominantly metabolised by CYP3A4 with minimal renal elimination.	Pemigatinib	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-50	
35506332-2	2022	It is primarily metabolized by cytochrome P450 (CYP)3A4, and the I/IC50 ratio for pemigatinib as an inhibitor of P-glycoprotein, (P-gp), organic cation transporter-2 (OCT2), and multidrug and toxin extrusion protein-1 (MATE1) exceed the cutoff values established in regulatory guidance.	Pemigatinib	82-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-55	
35506332-6	2022	The verified PBPK model was then used to predict the effect of other CYP3A4 inhibitors/inducers on pemigatinib PK and pemigatinib as an inhibitor of P-gp or OCT2/MATE1 substrates.	Pemigatinib	99-110	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75	
35506332-6	2022	The verified PBPK model was then used to predict the effect of other CYP3A4 inhibitors/inducers on pemigatinib PK and pemigatinib as an inhibitor of P-gp or OCT2/MATE1 substrates.	Pemigatinib	118-129	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75	
35153194-0	2022	Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminate in Mechanism-Based Inactivation of Cytochrome P450 3A.	Pemigatinib	39-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	134-152	
35153194-2	2022	Serendipitously, our preliminary data has also revealed that pemigatinib (PEM) - another clinically approved FGFR1-3 inhibitor - similarly elicited time-dependent inhibition of CYP3A.	Pemigatinib	61-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	177-182